Literature DB >> 2911166

Invasive pneumococcal disease in an Alaska native population, 1980 through 1986.

M Davidson1, C D Schraer, A J Parkinson, J F Campbell, R R Facklam, R B Wainwright, A P Lanier, W L Heyward.   

Abstract

From 1980 through 1986, one hundred fourteen Alaska Native patients from the Yukon-Kuskokwim Delta had community-acquired invasive pneumococcal disease confirmed by isolates of Streptococcus pneumoniae from normally sterile body sites. The annual bacteremia rates per 100,000 persons were 105 cases for all ages, 1195 cases for infants under 2 years of age, and 130 cases for adults over 59 years of age. These were six to 34 times higher than rates reported for other US populations. The most common underlying conditions in infants diagnosed before 24 months of age were previously diagnosed anemia and pneumonia, while alcoholism and anemia were most common in adults. The case-fatality rate for infants under 2 years of age was 3.2%, and the case-fatality rate for adults over 59 years of age was 30%. Serotyping of more than half the isolates identified 96% of these isolates to be present in the currently available pneumococcal polysaccharide vaccine. The pneumococcal disease rates reported herein are likely to be underestimates since most diseases that occur in this region are treated at the village level without laboratory confirmation.

Entities:  

Mesh:

Year:  1989        PMID: 2911166

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  12 in total

1.  Risk Factors for Pneumococcal Colonization of the Nasopharynx in Alaska Native Adults and Children.

Authors:  Jonathan Reisman; Karen Rudolph; Dana Bruden; Debby Hurlburt; Michael G Bruce; Thomas Hennessy
Journal:  J Pediatric Infect Dis Soc       Date:  2013-11-13       Impact factor: 3.164

Review 2.  Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.

Authors:  Tina Q Tan
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  Population-based study of acute respiratory infections in children, Greenland.

Authors:  Anders Koch; Per Sørensen; Preben Homøe; Kåre Mølbak; Freddy Karup Pedersen; Tine Mortensen; Hanne Elberling; Anne Mette Eriksen; Ove Rosing Olsen; Mads Melbye
Journal:  Emerg Infect Dis       Date:  2002-06       Impact factor: 6.883

Review 4.  Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility.

Authors:  Pui-Ying Iroh Tam; Beth K Thielen; Stephen K Obaro; Ann M Brearley; Alexander M Kaizer; Haitao Chu; Edward N Janoff
Journal:  Vaccine       Date:  2017-03-09       Impact factor: 3.641

5.  Comparison of methods of temperature measurement in swine.

Authors:  S K Hanneman; J T Jesurum-Urbaitis; D R Bickel
Journal:  Lab Anim       Date:  2004-07       Impact factor: 2.471

6.  Pneumococcal vaccination in a remote population of high-risk Alaska Natives.

Authors:  M Davidson; C Chamblee; H G Campbell; L R Bulkow; G E Taylor; A P Lanier; J Berner; J S Spika; W W Williams; J P Middaugh
Journal:  Public Health Rep       Date:  1993 Jul-Aug       Impact factor: 2.792

7.  Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia.

Authors:  K M Rudolph; A J Parkinson; C M Black; L W Mayer
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

8.  Pneumococcal bacteremia in Monroe County, New York.

Authors:  N M Bennett; J Buffington; F M LaForce
Journal:  Am J Public Health       Date:  1992-11       Impact factor: 9.308

9.  Seasonal patterns of invasive pneumococcal disease.

Authors:  Scott F Dowell; Cynthia G Whitney; Carolyn Wright; Charles E Rose; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

10.  Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants.

Authors:  Simon Rückinger; Mark van der Linden; Rüdiger von Kries
Journal:  BMC Infect Dis       Date:  2010-01-19       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.